TuHURA Biosciences, Inc.(HURA)
Search documents
TuHURA Biosciences, Inc.(HURA) - 2021 Q1 - Quarterly Report
2020-11-12 21:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37823 Kintara Therapeutics, Inc. (Exact name of registrant as specified in its charter) | Nevada | 99-0360497 | | --- | --- | | ( ...
TuHURA Biosciences, Inc.(HURA) - 2020 Q4 - Annual Report
2020-09-18 21:27
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 001-37823 Kintara Therapeutics, Inc. (Exact name of registrant as specified in its charter) | Nevada | | 99-0360497 | | --- | --- | --- | | (State or other ...
TuHURA Biosciences, Inc.(HURA) - 2020 Q3 - Quarterly Report
2020-05-13 12:49
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Nevada 99-0360497 (State or other jurisdiction of incorporation or organization) (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________________ Commission file number: 001-37823 DelMar Pharmaceu ...
TuHURA Biosciences, Inc.(HURA) - 2020 Q2 - Quarterly Report
2020-02-13 13:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________________ Commission file number: 001-37823 DelMar Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or ...
TuHURA Biosciences, Inc.(HURA) - 2020 Q1 - Quarterly Report
2019-11-13 21:56
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________________ Commission file number: 001-37823 DelMar Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or ...
TuHURA Biosciences, Inc.(HURA) - 2019 Q4 - Annual Report
2019-09-09 20:18
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 or Commission file number 001-37823 DelMar Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Nevada | 99-0360497 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 12707 High Bluff Dr., Suite 200 ...
TuHURA Biosciences, Inc.(HURA) - 2019 Q3 - Quarterly Report
2019-05-14 20:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________________ Commission file number: 001-37823 DelMar Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Nevada | 99 ...
TuHURA Biosciences, Inc.(HURA) - 2019 Q2 - Quarterly Report
2019-02-11 21:43
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________________ Commission file number: 001-37823 DelMar Pharmaceuticals, Inc. (Exact name of registrant as specified in its cha ...